Friedemann Übele

Head of Process Science • Tigen Pharma

Friede is a biotech engineer with a decade of experience in development and manufacturing of pharmaceutical products. He has a bachelors degree in biotechnology from the Esslingen University of Applied Sciences, Germany and a masters degree in process engineering from the University of Stuttgart, Germany. Within Novartis, he was involved in the build-up and operational launch of the first commercial Cell & Gene manufacturing facility for Novartis in Europe. His focus was on a paper free cleanroom and compliance to aseptic requirements. In 2021, Friede moved on to Tigen Pharma, a Swiss biotech company in the field of cell therapies to cure cancer. Tigen is a disruptive catalyst, combining a unique culture with a multidisciplinary set of clinical and technical capabilities and a long-term perspective to the benefit of patients and society.

Also speaking

Mark Throsby

Chief Scientific Officer • Gadeta

Elsa Abranches

Senior Director – Head of Cell Therapy Bioprocess Development and Manufacturing • AstraZeneca

Marcos Langtry

Director of Commercial Development, Allogeneic Cell Therapy • Lonza Ltd

Event Info


Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.

2022 Post-Event Report

Download the post-event report for Advanced Therapies Europe 2022.